GtreeBNT Aims To Validate Business Model Via Licensing Deals
Executive Summary
2017 may be a milestone year for GtreeBNT as it progresses its late clinical stage pipeline in the US for various high-need indications including glioblastoma, the South Korean bioventure’s CEO assuring investors that he expects to see “good results” in the near future as it seeks licensing deals for its assets.
You may also be interested in...
INTERVIEW: GtreeBNT Looks To Novelty, Deals To Become Dry Eye Player
GtreeBNT is looking to challenge one of the biggest ophthalmology sectors through a novel dry eye syndrome drug with multiple mechanisms of action that the South Korean venture believes can help it carve a significant global niche, helped by international licensing deals.
Shire To Launch Potential Dry Eye Blockbuster After FDA Backs Xiidra
Securing FDA approval for its novel dry eye treatment Xiidra (lifitegrast) gives Shire PLC a potential blockbuster and key future growth driver whose indication and label are more comprehensive than that of its closest approved rival.
New Korean Accounting Guidelines Aim For More Flexible Biopharma Practices
South Korea moves to lay out clearer accounting guidelines related to R&D costs for pharma and biotech companies, making improvements to earlier official guidance in 2018 in order to ease uncertainties and help foster the sector.